Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.
https://www.hal.inserm.fr/inserm-00484825 Contributor : Philippe SaasConnect in order to contact the contributor Submitted on : Wednesday, May 19, 2010 - 11:54:14 AM Last modification on : Friday, January 14, 2022 - 3:08:20 AM
Arlene Chan, D. W. Miles, Xavier Pivot. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.. Annals of Oncology, Elsevier, 2010, 21 (12), pp.2305-15. ⟨10.1093/annonc/mdq122⟩. ⟨inserm-00484825⟩